of human liver acid
β-galactosidases using affinity chromatography.
Anal. Biochem., 74 537-545 (1976).
4. Holmes, E. W. and O'Brien, J. S., Purification and
Properties of Acid β-Galactosidase from
of insulin-like growth factor-1-resistant
apoptosis by SC-ααδ9. J. Pharmacol. Exp. Ther.,
292, 530-537 (2000).
ProductInformation
6. Tamura, K. et al., Dual G1 and G2/M phase
inhibition by
2000).
5. Burt, D.J. et al., Diabetologia, 46, 531-537 (2003).
6. Degousee, N. et al., Circ Res., 92, 757-764 (2003).
7. Nemoto, S. et al., J. Biol. Chem., 273, 16415–
16420 (1998).
Sold for
human neutrophils requires nitric oxide-dependent
cGMP accumulation. J. Biol. Chem., 274, 537-542
(1999).
4. Stein, B., et al. Cloning and characterization of
MEK 6, a novel member of the mitogen
. Mori, M., et al., Dev. Biol., 146, 246 (1991).
4. Hirai, T., et al., Dev. Biol., 152, 113 (1992).
5. Yamashita, M., et al., Eur. J. Biochem., 205, 537
(1992).
6. Hirai, T., et al., Mol. Reprod. Dev
, M., Biosynthesis of the
epidermal growth factor receptor in A431 cells.
EMBO J, 3, 531-537. (1984).
4. Tang, C.K., et al. Epidermal growth factor receptor
vIII enhances tumorigenicity in human
, M., Biosynthesis
of the epidermal growth factor receptor in A431
cells. EMBO J., 3, 531-537 (1984).
4. Tang, C.K., et al., Epidermal growth factor
receptor VIII enhances tumorigenicity in human
comparison of selected mRNA
and protein abundances in human liver. Electrophoresis 1997,
18:533-537.
3. REFERENCES
http://www.sigmaaldrich.com
www.s igma-a ldr ich .com
7
34. Anderson
329 Negative Control NA
383 Negative Control NA
479 Negative Control NA
527 p16INK4a/CDKN2 P0968
537 Negative Control NA
545 p57kip2 P2735
570 Negative Control NA
572 Negative Control NA
611 Protein
329 Negative Control NA
383 Negative Control NA
479 Negative Control NA
527 p16INK4a/CDKN2 P0968
537 Negative Control NA
545 p57kip2 P2735
570 Negative Control NA
572 Negative Control NA
611 Protein
329 Negative Control NA
383 Negative Control NA
479 Negative Control NA
527 p16INK4a/CDKN2 P0968
537 Negative Control NA
545 p57kip2 P2735
570 Negative Control NA
572 Negative Control NA
611 Protein
M8432 M y y y
535 p38 MAPK M0800 P n/d y y
536 p38 MAPK activated (diphosphorylated p38) M8177 M y y y
537 Negative Control NA
538 p53 P5813 M y n/d n/d
539 p53 P6874 M y n/d n/d
540 phospho-p53 (pSer392) P8982
diphosphorylated p38) M8177 26416, 1432, 81649 Mapk14,MAPK14 NP_036081.1,NP_620583.1,NP_112282.2 M y y y
537 Negative Control
538 p53 P5813 7157 TP53 NP_000537.3 M y n/d n/d
539 p53 P6874 7157 TP53 NP_000537.3
diphosphorylated p38) M8177 26416, 1432, 81649 Mapk14,MAPK14 NP_036081.1,NP_620583.1,NP_112282.2 M y y y
537 Negative Control NA
538 p53 P5813 7157 TP53 NP_000537.3 M y n/d n/d
539 p53 P6874 7157 TP53 NP_000537.3